RETN and atherosclerosis: While its direct causal role in insulin resistance remains debated in human studies, resistin’s consistent association with endothelial dysfunction, atherosclerosis, and adverse cardiac outcomes highlights its potential as both a biomarker and therapeutic target in cardiometabolic diseases.